LEASE by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company and SURFACE ONCOLOGY, INC., a Delaware corporationLease • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 13th day of May, 2016 (the “Execution Date”), by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company (“Landlord”), and SURFACE ONCOLOGY, INC., a Delaware corporation (“Tenant”).
FORM OF OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [________________] by and between EQRx, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”).
FORM OF DIRECTOR INDEMNIFICATION AGREEMENTForm of Director Indemnification Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [________] by and between EQRx, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”).
EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN CSTONE PHARMACEUTICALS AND EQRX, INC. DATED AS OF OCTOBER 26, 2020Exclusive License Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of October 26, 2020 (the “Execution Date”) by and among CStone Pharmaceuticals, a corporation organized and existing under the laws of the Cayman Islands, with a registered address at P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands (“Licensor”), and EQRX, INC., a Delaware corporation having its principal place of business at 399 Binney St, Cambridge, MA 02141 (“EQRx”). Licensor and EQRx are referred to herein individually as a “Party” and collectively as the “Parties.”
EQRx, Inc. 50 Hampshire St. Cambridge, MA 02139Letter Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • Massachusetts
This amended and restated letter agreement (the “letter agreement”) confirms the amended and restated terms and conditions of your employment with EQRx, Inc. (the “Company”) and amends and restates and supersedes in all respects your Employment Letter Agreement dated November 11, 2019 (the “Former Agreement”), provided that the Company’s Employee Confidentiality, Assignment and Noncompetition Agreement that you signed with your Former Agreement, which is attached as Exhibit A, remains in full effect. You acknowledge and agree that nothing in this letter agreement constitutes “Good Reason” under the Former Agreement, or any other agreement between you and the Company.
EQRx, Inc. 50 Hampshire St. Cambridge, MA 02139Employment Letter Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • Massachusetts
This amended and restated letter agreement (the “letter agreement”) confirms the amended and restated terms and conditions of your employment with EQRx, Inc. (the “Company”) and amends and restates and supersedes in all respects your Employment Letter Agreement dated November 11, 2019 (the “Former Agreement”), provided that the Company’s Employee Confidentiality, Assignment and Noncompetition Agreement that you signed with your Former Agreement, which is attached as Exhibit A, remains in full effect. You acknowledge and agree that nothing in this letter agreement constitutes “Good Reason” under the Former Agreement, or any other agreement between you and the Company.
March 8, 2021 Jami Rubin RE: Employment Letter Agreement Dear Jami:CM Life Sciences III Inc. • October 4th, 2021 • Pharmaceutical preparations • Massachusetts
On behalf of EQRx, Inc. (the “Company”), I am pleased to offer you the position of the Company’s Chief Financial Officer. If accepted, this letter agreement sets forth the terms and conditions of your employment.
STRATEGIC COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN HANSOH (SHANGHAI) HEALTHTECH CO., LTD. JIANGSU HANSOH PHARMACEUTICAL GROUP COMPANY LTD. AND EQRX, INC. DATED AS OF JULY 22, 2020Strategic Collaboration and License Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • New York
THIS STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of July 22, 2020 (the “Effective Date”), by and among HANSOH (SHANGHAI) HEALTHTECH CO., LTD., a corporation incorporated under the laws of China having its principal place of business at Room 102, Block 1 No.298 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh Healthtech”) and JIANGSU HANSOH PHARMACEUTICAL GROUP COMPANY LTD., a corporation incorporated under the laws of China having its principal place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyuangang, Jiangsu, China (“Jiangsu Hansoh” and together with Hansoh Healthtech, “Hansoh”), and EQRX, INC., a Delaware corporation having its principal place of business at 50 Hampshire St., Cambridge, MA 02139, United States (“EQRx”). Hansoh and EQRx are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SUBLEASESublease Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations • Massachusetts
THIS SUBLEASE AGREEMENT (this “Sublease”), made as of December 16, 2019 (the “Effective Date”), by and between SURFACE ONCOLOGY, INC., a Delaware corporation (“Sublessor”), and EQRX, INC., a Delaware corporation (hereinafter referred to as “Sublessee”);
EQRX, INC. FOUNDER AGREEMENTFounder Agreement • October 4th, 2021 • CM Life Sciences III Inc. • Pharmaceutical preparations
THIS FOUNDER AGREEMENT (this “Agreement”) is made and entered into as of December 19 , 2019 by and between Sandra J. Homing, MD, an individual (“Founder”), whose address is set forth on the last page below and EQRx, Inc., a Delaware corporation (the “Company”), whose address is set forth on the last page below.
